Vernalis Announces New Oncology Development Candidate
Following treatment with cytotoxic drugs, some cancer cells use the Chk1 pathway to increase cell survival by pausing DNA replication and allowing repair of the damaged DNA before completing cell division. Inhibition of the Chk1 enzyme blocks this pathway, forcing cells to divide (mitosis), causing substantial DNA damage that results in their death.
The aim of this programme was to identify product candidates that increase the anti-tumour efficacy of current cytotoxic agents without increasing their toxicity to non-cancerous tissues. V158411 has met these goals in pre-clinical cancer models when administered with commonly used cytotoxic agents, and has drug-like characteristics and appropriate pharmacokinetic properties.
Because Chk1 inhibitors are used in conjunction with chemotherapy drugs, they can potentially be used to treat a broad range of tumour types including breast, prostate, colorectal and melanoma. They may also be used in haematological cancers such as leukaemia.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.